background
diagnosi
ventilatorassoci
pneumonia
vap
remain
timeconsum
costli
clinic
tool
lack
specif
bedsid
test
exclud
infect
suspect
patient
unavail
breath
contain
hundr
thousand
volatil
organ
compound
voc
result
host
microbi
metabol
well
environ
present
studi
aim
use
breath
voc
analysi
develop
model
discrimin
patient
posit
cultur
neg
cultur
high
sensit
methodsdesign
molecular
analysi
exhal
breath
diagnost
test
ventilatorassoci
pneumonia
breathdx
studi
multicentr
observ
studi
breath
bronchial
lavag
sampl
collect
intub
ventil
patient
suspect
vap
breath
analys
use
thermal
desorpt
ga
chromatographi
mass
spectrometri
tdgcm
primari
endpoint
accuraci
crossvalid
predict
posit
respiratori
cultur
patient
suspect
vap
sensit
least
high
neg
predict
valu
discuss
knowledg
breathdx
first
studi
power
investig
whether
molecular
analysi
breath
use
classifi
suspect
vap
patient
without
posit
microbiolog
cultur
sensit
trial
registr
ukcrn
id
number
regist
may
well
registr
wwwtrialregisternl
acronym
breathdx
trial
id
number
ntr
retrospect
regist
octob
ventilatorassoci
pneumonia
vap
frequent
complic
mechan
ventil
intens
care
unit
icu
associ
morbid
result
substanti
healthcar
cost
diagnosi
vap
remain
challeng
clinic
laboratori
radiolog
paramet
sensit
nonspecif
vap
suffer
high
interrat
variabl
lower
respiratori
tract
sampl
bronchoalveolar
lavag
bal
endotrach
aspir
protect
specimen
brush
sampl
recommend
microbiolog
confirm
clinic
suspect
vap
result
take
day
becom
avail
procedur
repeat
frequent
due
invas
result
delay
patient
overtr
antibiot
empir
antibiot
treatment
initi
immedi
obtain
lower
respiratori
tract
sampl
subsequ
microbiolog
result
help
tailor
deescal
antibiot
treatment
lower
respiratori
tract
sampl
continu
crucial
import
diagnos
vap
need
less
invas
timeeffici
diagnost
techniqu
ultim
reduc
amount
antibiot
use
treat
suspect
vap
clinic
score
system
like
clinic
pulmonari
infect
score
cpi
biomark
studi
mean
exclud
vap
far
attempt
result
test
suitabl
current
icu
practic
exhal
breath
contain
volatil
organ
compound
voc
small
volatil
molecul
result
host
bacteri
metabol
contamin
environ
exhal
voc
profil
shown
differenti
mani
differ
diseas
state
may
therefor
qualifi
noninvas
biomark
captur
voc
exhal
breath
analysi
proven
safe
reliabl
mechan
ventil
critic
ill
patient
data
invitro
experi
suggest
presenc
bacteria
may
detect
base
small
panel
voc
concept
recent
translat
vivo
ventil
patient
without
posit
bacteri
cultur
endotrach
aspir
could
discrimin
base
exhal
voc
aim
studi
determin
whether
molecular
analysi
breath
use
discrimin
patient
suspect
vap
posit
cultur
neg
cultur
high
sensit
thu
potenti
limit
antibiot
use
secondli
hypothes
molecular
analysi
breath
use
specif
detect
caus
pathogen
patient
suspect
vap
offer
possibl
target
antibiot
therapi
patient
recruit
sampl
collect
within
h
clinic
suspicion
vap
first
breath
sampl
collect
follow
bronchoscopi
bronchial
lavag
standard
oper
procedur
sop
place
site
order
ensur
sampl
collect
equal
breath
sampl
ship
within
day
collect
shall
analys
within
week
upon
arriv
previou
result
shown
breath
sampl
store
least
day
without
loss
data
mini
bal
sampl
process
frozen
immedi
recruit
mini
bal
sampl
collect
ship
dri
ice
remain
conserv
breath
sampl
collect
time
recruit
use
breath
ga
sampler
bg
see
fig
consist
pump
micro
membranega
pump
mass
flow
control
horiba
stec
batteri
charger
panason
ideal
power
combin
metal
case
oper
display
brook
instrument
use
bg
ptfe
polytetrafluoroethylen
tube
swagelok
warrington
uk
exhal
breath
drawn
sidearm
tpiec
connector
insert
ventil
circuit
distal
hme
filter
stainless
steel
sorbent
tube
mark
intern
llantris
uk
gerstel
der
ruhr
germani
adapt
bo
et
al
subsequ
sorbent
tube
transport
offsit
analysi
sampl
linkanonymis
two
pair
collect
per
patient
sent
two
differ
laboratori
locat
analysi
one
pair
philip
research
eindhoven
netherland
manchest
institut
biotechnolog
univers
manchest
manchest
unit
kingdom
analysi
philip
research
exhal
breath
collect
use
sorbent
tube
pack
mg
carbograph
mark
intern
llantris
uk
mg
tenax
gr
sigmaaldrich
chemi
bv
zwijndrecht
netherland
sampl
analys
manchest
institut
biotechnolog
collect
use
sorbent
tube
pack
mg
tenax
gr
mark
intern
llantris
uk
sampl
taken
duplic
breath
sampl
store
cold
room
immedi
collect
sampl
setup
shown
safe
adequ
sampl
collect
ventil
icu
patient
mini
bal
sampl
obtain
microbiolog
analysi
soon
possibl
collect
breath
sampl
see
fig
syring
connect
bronchoscop
cm
suction
cathet
ml
salin
inject
airway
least
ml
aspir
ml
sent
medic
microbiolog
routin
cultur
lead
semiquantit
bacteri
count
cutoff
coloni
form
unitsml
defin
posit
cultur
aliquot
mini
bal
sampl
process
store
futur
analysi
exhal
breath
sampl
analys
use
thermal
desorpt
ga
chromatographi
massspectrometri
tdgcm
order
separ
quantifi
identifi
wide
rang
volatil
breath
differ
chromatograph
setup
eindhoven
manchest
use
gcm
analys
result
list
detect
volatil
rel
concentr
philip
research
sorbent
tube
thermal
desorb
tdsa
gerstel
der
ruhr
germani
gc
capillari
column
solvent
vent
mode
use
transfer
sampl
without
loss
pack
liner
fill
tenax
ta
held
subsequ
heat
cold
trap
gerstel
der
ruhr
germani
use
minim
band
broaden
initi
temperatur
min
heat
capillari
ga
chromatograph
n
gc
agil
santaclara
ca
usa
use
column
length
intern
diamet
mm
film
thick
dimethylpolysiloxan
varian
chrompack
middelburg
netherland
use
follow
temperatur
program
min
ramp
hold
min
ramp
ramp
ramp
ramp
hold
min
timeofflight
mass
spectromet
pegasu
system
leco
st
joseph
mi
usa
use
electron
ioniz
mode
ev
scan
rang
mz
da
scan
rate
scanss
gaseou
calibr
standard
ppmv
nitrogen
air
product
amsterdam
netherland
made
use
homebuilt
dilut
system
load
adsorpt
tube
intern
standard
manchest
institut
biotechnolog
sorbent
tube
fill
tenax
gr
thermal
desorb
mark
intern
llantris
uk
cold
trap
minim
band
broaden
initi
temperatur
min
heat
fed
capillari
ga
chromatograph
gc
agil
santaclara
ca
usa
use
ms
ultra
inert
column
length
intern
diamet
mm
film
thick
phenyl
methylpolysiloxan
agil
santaclara
ca
usa
follow
temperatur
program
min
ramp
hold
min
ramp
total
time
min
triplequad
mass
spectromet
agil
santaclara
ca
usa
use
electron
ioniz
mode
ev
scan
rang
mz
da
scan
rate
scanss
gaseou
calibr
standard
ppmv
nitrogen
thame
restek
uk
load
adsorpt
tube
intern
standard
min
mlmin
addit
aid
retent
time
correct
extern
standard
contain
mixtur
laboratori
standard
voc
chemic
sigma
aldrich
uk
sampl
separ
tube
either
side
breath
sampl
clinic
data
regard
patient
characterist
primari
secondari
diagnos
comorbid
drug
histori
measur
diseas
sever
acut
physiolog
chronic
health
evalu
apach
iv
simplifi
acut
physiolog
score
sap
ii
ventil
data
cpi
cultur
data
outcom
variabl
icuhospit
length
stay
mortal
advers
event
collect
primari
endpoint
accuraci
crossvalid
predict
posit
respiratori
cultur
patient
suspect
vap
sensit
least
high
neg
predict
valu
secondari
endpoint
accuraci
crossvalid
predict
growth
specif
pathogen
specif
least
gcm
identifi
molecular
marker
distinguish
patient
without
microbiolog
confirm
vap
p
fals
discoveri
rate
gcm
identifi
molecular
marker
distinguish
patient
without
growth
specif
pathogen
bacteri
cultur
p
fals
discoveri
rate
accuraci
predict
within
subgroup
patient
without
previou
respiratori
infect
accuraci
predict
within
subgroup
patient
intub
less
week
sampl
size
calcul
perform
base
binomi
distribut
instead
normal
approxim
distribut
expect
sensit
almost
neg
predict
valu
requir
lower
confid
limit
larger
probabl
sensit
absolut
minim
discoveri
studi
lower
sensit
clinic
irrelev
would
clinic
use
figur
requir
number
case
estim
assum
preval
posit
cultur
bronchoalveolar
lavag
patient
clinic
suspect
vap
total
studi
sampl
size
subject
gcm
data
threedimension
natur
ion
count
everi
combin
mz
valu
retent
time
chromatogram
repres
total
ion
count
tic
measur
gcm
function
retent
time
first
step
preprocess
consist
correct
chromatograph
baselin
requir
proper
estim
ion
intens
accur
molecul
identif
base
mass
spectra
subsequ
data
visual
inspect
exclud
contamin
sampl
contamin
sampl
tube
eg
due
loos
fit
transport
sever
distort
store
breath
content
tube
exclud
analysi
peak
detect
use
method
describ
smith
et
al
implement
rpackag
xcm
current
cite
preprocess
tool
metabolom
literatur
set
peak
detect
determin
describ
smith
et
al
use
model
peak
width
consider
larger
signal
peak
time
consist
signaltonois
improv
intens
intern
standard
use
normal
peak
gcm
data
two
laboratori
respect
retent
time
align
xcm
packag
work
well
rel
small
retent
time
shift
larg
shift
method
becom
inaccur
result
loss
peak
final
tabl
erron
align
sampl
experi
sampl
measur
time
span
least
month
therefor
rather
larg
retent
time
shift
expect
account
retent
time
shift
follow
approach
appli
consist
two
step
first
major
part
time
shift
correct
use
anchor
point
marker
molecul
ie
molecul
clearli
identifi
mass
spectra
distribut
full
retent
time
window
exampl
isopren
toluen
compound
intern
standard
molecul
identifi
compar
measur
mass
spectra
spectra
publish
nation
institut
standard
technolog
nist
chemistri
web
book
databas
use
dotproduct
function
similar
measur
accord
stein
scott
algorithm
give
best
similar
estim
mass
spectra
first
raw
retent
time
correct
perform
use
linear
quadrat
fit
retent
time
marker
molecul
second
step
approach
consist
fine
align
use
regular
retent
time
correct
xcm
packag
describ
smith
et
al
step
result
ionfrag
peak
tabl
row
tabl
correspond
sampl
first
column
contain
sampl
patient
data
sampl
data
age
gender
ill
remain
column
contain
abund
peak
ionfrag
typic
thousand
tabl
serv
input
extra
qualiti
check
subsequ
statist
analysi
one
qualiti
check
consist
compar
two
pair
sampl
success
collect
patient
content
duplic
equival
especi
compar
content
arbitrari
sampl
cosin
similar
measur
plot
histogram
duplic
sampl
arbitrari
sampl
equal
distribut
histogram
test
twosid
kolmogorovsmirnov
test
addit
intens
sever
common
molecul
replic
sampl
analys
use
blandaltman
plot
sampl
measur
differ
gcm
instrument
rare
ident
due
multipl
differ
technic
characterist
previou
attempt
align
data
differ
gcm
machin
prove
complic
therefor
sampl
differ
gcm
machin
align
separ
gcm
machin
fragment
averag
two
consecut
sampl
summar
peak
intens
way
number
breath
featur
becom
roughli
twice
larg
newli
ad
featur
correl
exist
featur
sinc
sequenti
sampl
patient
depend
featur
higher
number
featur
put
higher
strain
statist
analysi
data
use
data
discoveri
untarget
analysi
target
analysi
data
discoveri
consist
principl
compon
analysi
pca
logtransform
scale
data
ward
cluster
abund
peak
elut
least
one
second
apart
well
relev
principl
compon
untarget
analysi
consist
build
predict
model
base
data
model
reduc
dimension
dataset
number
featur
mani
time
higher
number
patient
increas
risk
overfit
addit
featur
independ
sever
ion
fragment
origin
molecul
statist
model
need
abl
deal
final
breath
data
typic
show
larg
variat
voc
abund
also
within
individu
consid
characterist
data
chosen
spars
partial
least
squar
model
analys
logtransform
data
small
number
includ
patient
allow
data
split
train
set
valid
set
although
prefer
method
instead
permut
test
use
estim
perform
model
target
approach
exist
literatur
search
potenti
biomark
vap
abund
molecul
compar
patient
group
use
student
ttest
mannwhitneywilcoxon
test
normal
nonnorm
distribut
data
respect
import
advantag
approach
low
likelihood
fals
discoveri
amount
comparison
limit
previou
find
valid
order
assess
influenc
possibl
confound
eg
comorbid
ventil
set
medic
associ
exhal
breath
vap
log
odd
ratio
compar
logist
regress
model
voc
interest
depend
variabl
vap
yesno
independ
variabl
model
inclus
potenti
confound
covari
log
odd
ratio
show
chang
covari
consid
confound
studi
end
requir
sampl
size
reach
result
report
strictli
follow
standard
report
diagnost
accuraci
stard
guidelin
manuscript
describ
protocol
multicentr
prospect
observ
studi
aim
develop
diagnost
tool
discrimin
patient
suspect
vap
posit
cultur
neg
cultur
breath
analysi
use
tdgcm
addit
aim
describ
pattern
voc
exhal
breath
predict
presenc
specif
pathogen
ultim
strive
diagnost
test
sensit
cultur
posit
vap
requir
icu
set
delay
initi
adequ
antibiot
therapi
unaccept
sever
clinic
challeng
recogn
studi
priori
first
report
incid
vap
declin
last
decad
recruit
depend
clinic
suspicion
vap
could
slow
inclus
rate
clinic
definit
inclus
studi
could
also
seen
weak
studi
clinic
practic
may
vari
hospit
hospit
howev
tri
includ
hospit
wide
varieti
set
countri
throughout
europ
cover
heterogen
clinic
practic
geograph
variat
may
also
introduc
nois
data
collect
breath
analysi
environ
contribut
exhal
voc
anoth
challeng
concern
secondari
aim
studi
identifi
pattern
voc
predict
presenc
specif
caus
pathogen
number
voc
alreadi
associ
certain
pathogen
larg
number
pathogen
caus
vap
group
patient
like
infect
pathogen
risk
inher
prospect
clinic
studi
expect
find
suffici
larg
group
patient
least
import
pathogen
vap
pseudomona
aeruginosa
staphylococcu
aureu
enterobacteriacea
also
multipl
analyt
challeng
patient
recruit
minimum
period
result
gcm
platform
stabl
period
time
potenti
column
degrad
chang
retent
time
voc
sever
member
consortium
previous
perform
studi
similarli
long
period
time
develop
statist
tool
correct
shift
retent
time
sensit
mass
spectromet
may
also
drift
problem
previou
studi
therefor
intern
standard
includ
present
protocol
studi
focus
breath
analysi
alway
challeng
statist
overfit
expect
find
sever
hundr
voc
breath
patient
use
predictor
presenc
vap
high
dimension
predictor
matrix
easili
result
fals
discoveri
therefor
suffici
intern
valid
measur
must
taken
suggest
two
approach
protocol
first
aim
valid
previous
found
marker
limit
number
statist
comparison
increas
chang
valid
discoveri
second
novel
biomark
discov
use
crossvalid
permut
test
describ
protocol
also
sever
strength
pragmat
natur
studi
popul
clinic
relev
treatment
decis
may
influenc
outcom
test
use
unbias
approach
patient
recruit
multipl
european
countri
breath
analysi
multipl
gcm
platform
studi
allow
develop
test
applic
wide
varieti
hospit
special
attent
given
analyt
versatil
multipl
sorbent
bed
use
breath
analys
two
separ
platform
complementari
analyt
strength
also
addit
intellectu
benefit
result
may
translat
patient
identifi
marker
may
also
studi
patient
suspect
communityor
hospitalacquir
pneumonia
anoth
possibl
valu
within
result
develop
continu
breath
test
warn
clinician
patient
develop
pneumonia
result
studi
direct
clinic
implic
sensit
reach
maintain
moder
good
specif
antibiot
treatment
withheld
larg
proport
vapsuspect
patient
preval
cultur
posit
vap
everi
patient
would
benefit
scenario
sensit
specif
obtain
antibiot
therapi
could
withheld
four
patient
case
figur
improv
increas
specif
preselect
sensit
lower
preval
cultur
posit
vap
conclus
hypothes
breath
analysi
use
discrimin
vap
suspect
patient
without
microbiolog
posit
cultur
high
sensit
use
specif
detect
caus
strain
bacteria
patient
recruit
breathdx
studi
current
ongo
